

Amendments to the Claims:


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

What is claimed is:

1 – 8. (Canceled)


9. (Previously presented) A compound of formula (I):



(I)

wherein:

R¹ represents a group selected from:



each ring of which optionally contains a further heteroatom N,
 Z represents an optional substituent halogen,
 alk represents alkylene or alkenylene,
 T represents S, O or NH;

R^2 represents hydrogen, $-C_{1-6}alkyl$, $-C_{1-3}alkylCONR^aR^b$, $-C_{1-3}alkylCO_2C_{1-4}alkyl$, $-C_{2-3}alkylmorpholino$, $-CO_2C_{1-4}alkyl$, or $-C_{1-3}alkylCO_2H$;

R^a and R^b independently represent hydrogen, $-C_{1-6}alkyl$, or together with the N atom to which they are bonded form a 5-, 6- or 7- membered non-aromatic heterocyclic ring optionally containing an additional heteroatom selected from O, N or S, optionally substituted by $-C_{1-4}alkyl$, and optionally the S heteroatom is substituted by (O)_n;

n represents 0-2;

X represents phenyl or a 5- or 6- membered aromatic heterocyclic group containing at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: halogen, $-C_{1-4}alkyl$, $-C_{2-4}alkenyl$, $-CN$, $-CF_3$, $-NR^aR^b$, $-C_{0-4}alkylOR^e$, $-C(O)R^f$ and $-C(O)NR^aR^b$;

R^e represents hydrogen or $-C_{1-6}alkyl$;

R^f represents $-C_{1-6}alkyl$;


Y is absent or represents $-C_{1-3}alkylene-$;

R³ represents hydrogen or -C₁₋₆alkyl;

R⁴ represents -C₃₋₄alkenyl, -CH₂CH₂OH, -CH₂CO₂H, -CH₂CH₂OC₁₋₃alkyl, -CH₂CH₂SO₂C₁₋₃alkyl, -CH₂CH₂NR^cR^d, -CH₂CONR^cR^d, phenyl or a 5- or 6- membered aromatic or non-aromatic heterocyclic group containing at least one heteroatom selected from O, N or S and optionally substituted by -C₁₋₄alkyl;

R^c and R^d independently represent hydrogen, -C₁₋₆alkyl, or together with the N atom to which they are bonded form a 5-, 6- or 7- membered non-aromatic heterocyclic ring optionally containing an additional heteroatom selected from O, N or S, optionally substituted by -C₁₋₄alkyl;
or a pharmaceutically acceptable salt thereof.

10. (Previously presented) A compound according to claim 9, wherein R¹ represents a group selected from:



each ring of which optionally contains a further heteroatom N,

Z represents an optional substituent halogen,

alk represents alkylene or alkenylene,

T represents S, O or NH;

or a pharmaceutically acceptable salt thereof.

11. (Previously presented) A compound according to claim 9 wherein R² represents hydrogen, or a pharmaceutically acceptable salt thereof.

12. (Previously presented) A compound according to claim 9, wherein X represents phenyl or a 5- or 6- membered aromatic heterocyclic group containing at least one heteroatom

selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: halogen, -C₁₋₄alkyl or -NR^aR^b, or a pharmaceutically acceptable salt thereof.

13. (Previously presented) A compound according to claim 9, wherein Y is absent or represents C₁₋₂ alkylene, or a pharmaceutically acceptable salt thereof.

14. (Previously presented) A compound according to claim 9, wherein R³ represents hydrogen or methyl, or a pharmaceutically acceptable salt thereof.

15. (Previously presented) A compound according claim 9, wherein R⁴ represents -C₃₋₄alkenyl, -CH₂CH₂OH, -CH₂CO₂H, -CH₂CH₂OCH₃, -CH₂CH₂SO₂CH₃, -CH₂CH₂NR^cR^d, -CH₂CONR^cR^d, phenyl or a 5- or 6- membered aromatic heterocyclic group containing one or two heteroatoms selected from O, N or S and optionally substituted by -C₁₋₄alkyl, or a pharmaceutically acceptable salt thereof.

16. (Previously presented) A compound according to claim 9, selected from:
4-[3-({[(1E)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(methylamino)ethyl]benzamide;
4-[3-({[(1E)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-N-(2-hydroxyethyl)-N-methylbenzamide;
4-[3-({[(1E)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-(2-pyridinylmethyl)benzamide;
4-[3-({[(1E)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(methylsulfonyl)ethyl]benzamide;
4-[3-({[(1E)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(methyloxy)ethyl]benzamide;
4-[3-({[(E)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(3-pyridinyl)ethyl]benzamide;
4-[3-({[(E)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-(2-phenylethyl)benzamide;
4-[3-({[(E)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-N-(4-pyridinylmethyl)benzamide;
4-[3-({[(E)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-N-(3-pyridinylmethyl)benzamide;
4-[3-({[(E)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-N-(2-hydroxyethyl)-N-methylbenzamide;
4-[3-({[(E)-2-(5-Chloro-2-thienyl)ethenyl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-N-(phenylmethyl)benzamide;



4-[3-({(E)-2-(5-Chloro-2-thienyl)ethenyl)sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(methoxy)ethyl]benzamide;
4-[3-({(E)-2-(5-Chloro-2-thienyl)ethenyl)sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-N-[2-(dimethylamino)ethyl]-3-fluoro-N-methylbenzamide;
4-[3-({(E)-2-(5-Chloro-2-thienyl)ethenyl)sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(methylsulfonyl)ethyl]benzamide;
4-[3-({(E)-2-(5-Chloro-2-thienyl)ethenyl)sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-2-propen-1-ylbenzamide;
N-(2-Amino-2-oxoethyl)-4-[3-({(E)-2-(5-chloro-2-thienyl)ethenyl)sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methylbenzamide;
4-[3-({(E)-2-(5-Chloro-2-thienyl)ethenyl)sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-(4-pyridinylmethyl)benzamide;
4-[3-({(E)-2-(5-Chloro-2-thienyl)ethenyl)sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(1-pyrrolidinyl)ethyl]benzamide;
4-[3-({(E)-2-(5-Chloro-2-thienyl)ethenyl)sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-N-[2-(1H-imidazol-4-yl)ethyl]-N-methylbenzamide;
4-[3-({(E)-2-(5-Chloro-2-thienyl)ethenyl)sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-N-(3-hydroxypropyl)-N-methylbenzamide;
4-[3-({(E)-2-(5-Chloro-2-thienyl)ethenyl)sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[3-(methylamino)-3-oxopropyl]benzamide;
4-[3-({(E)-2-(5-Chloro-2-thienyl)ethenyl)sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(4-methyl-1H-imidazol-5-yl)ethyl]benzamide;
N-({4-[3-({(E)-2-(5-Chloro-2-thienyl)ethenyl)sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluorophenyl)carbonyl)-N-methylglycine;
N-({4-[3-({(E)-2-(5-Chloro-2-thienyl)ethenyl)sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluorophenyl)carbonyl)glycine;
4-(3-({(6-Chloro-1-benzothien-2-yl)sulfonyl}amino)-2-oxo-1-pyrrolidinyl)-N-[2-(dimethylamino)ethyl]-3-fluoro-N-methylbenzamide;
4-(3-({(6-Chloro-1-benzothien-2-yl)sulfonyl}amino)-2-oxo-1-pyrrolidinyl)-3-fluoro-N-methyl-N-[2-(methylamino)ethyl]benzamide;
4-(3-({(6-Chloro-1-benzothien-2-yl)sulfonyl}amino)-2-oxo-1-pyrrolidinyl)-3-fluoro-N-methyl-N-[2-(3-pyridinyl)ethyl]benzamide;
N-(2-Aminoethyl)-4-(3-({(6-chloro-1-benzothien-2-yl)sulfonyl}amino)-2-oxo-1-pyrrolidinyl)-3-fluoro-N-methylbenzamide;
4-[3-({(1E)-2-(5-Chloro-2-thienyl)-1-propen-1-yl)sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-N-[2-(dimethylamino)ethyl]-3-fluoro-N-methylbenzamide;
4-[3-({(1E)-2-(5-Chloro-2-thienyl)-1-propen-1-yl)sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(3-pyridinyl)ethyl]benzamide;

4-[3-({[(1*E*)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N*-[2-(1*H*-imidazol-4-yl)ethyl]-*N*-methylbenzamide; and
4-(3-{{[(6-Chloro-2-naphthalenyl)sulfonyl]amino}-2-oxo-1-pyrrolidinyl)-3-fluoro-*N*-methyl-*N*-[2-(methylamino)ethyl]benzamide;
or a pharmaceutically acceptable salt thereof.

17. (Withdrawn) A pharmaceutical composition comprising a compound according to claim 9 together with a pharmaceutical carrier and/or excipient.


18. (Withdrawn) A method of treating a patient suffering from a condition susceptible to amelioration by a Factor Xa inhibitor comprising administering a therapeutically effective amount of a compound according to claim 9.

19. (Withdrawn) A process for preparing a compound of formula (I) which comprises:
(a) reacting compound of formula (II) or an acid addition salt thereof with a compound of formula (III) where V is a suitable leaving group:



OR:

(b) by reacting compounds of formula (XIII) with compounds of formula (VI):



(c) by reacting a compound of formula (I) where R^2 is hydrogen with a compound of formula (XVII):



where R^2 is $-C_{1-6}\text{alkyl}$, $-C_{1-3}\text{alkylCONR}^a\text{R}^b$, $-C_{1-3}\text{alkylCO}_2C_{1-4}\text{alkyl}$, $-C_{2-3}\text{alkylmorpholino}$ or $-CO_2C_{1-4}\text{alkyl}$ and T is a suitable leaving group, optionally followed by removal of the alkyl protecting group where appropriate.